Illumina, Inc.
$131.09
▼
-0.67%
2026-04-22 10:12:13
www.illumina.com
NMS: ILMN
Explore Illumina, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$19.95 B
Current Price
$131.09
52W High / Low
$155.53 / $69.83
Stock P/E
24.09
Book Value
$17.8
Dividend Yield
—
ROCE
16.15%
ROE
33.36%
Face Value
—
EPS
$5.45
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
8,600
Beta
1.49
Debt / Equity
93.76
Current Ratio
2.08
Quick Ratio
1.72
Forward P/E
20.75
Price / Sales
4.26
Enterprise Value
$19.41 B
EV / EBITDA
17.04
EV / Revenue
4.47
Rating
Buy
Target Price
$136.11
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 2. | Agilent Technologies, Inc. | $122.3 | 26.99 | $34.7 B | 0.84% | 14.25% | 19.95% | $160.27 / $99.12 | $24.44 |
| 3. | OPKO Health, Inc. | $1.22 | — | $926.06 M | — | -12.27% | -17.14% | $1.6 / $1.09 | $1.67 |
| 4. | ENDRA Life Sciences Inc. | $6.01 | — | $7.46 M | — | -281.17% | -2.92% | $11.96 / $2.9 | $0.22 |
| 5. | Exagen Inc. | $2.99 | — | $72.61 M | — | -32.08% | -1.48% | $12.23 / $2.59 | $0.76 |
| 6. | GRAIL, Inc. | $51.2 | — | $2.1 B | — | -18.79% | -16.07% | $118.84 / $25.56 | $63.92 |
| 7. | NeoGenomics, Inc. | $8.23 | — | $1.06 B | — | -6.93% | -12.43% | $13.74 / $4.72 | $6.49 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.16 B | 1.08 B | 1.06 B | 1.04 B | 1.1 B | — |
| Operating Profit | 211 M | 227 M | 214 M | 164 M | 193 M | — |
| Net Profit | 334 M | 150 M | 235 M | 131 M | 187 M | — |
| EPS in Rs | 2.2 | 0.99 | 1.55 | 0.86 | 1.23 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.34 B | 4.37 B | 4.5 B | 4.58 B |
| Operating Profit | 817 M | 600 M | -222 M | 354 M |
| Net Profit | 850 M | -1.22 B | -1.16 B | -4.4 B |
| EPS in Rs | 5.6 | -8.05 | -7.64 | -28.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.64 B | 6.3 B | 10.11 B | 12.25 B |
| Total Liabilities | 3.92 B | 3.93 B | 4.37 B | 5.65 B |
| Equity | 2.72 B | 2.37 B | 5.75 B | 6.6 B |
| Current Assets | 3.29 B | 2.75 B | 2.61 B | 3.56 B |
| Current Liabilities | 1.58 B | 1.55 B | 1.57 B | 2.77 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.08 B | 837 M | 478 M | 392 M |
| Investing CF | -55 M | -178 M | -231 M | -591 M |
| Financing CF | -744 M | -570 M | -1.21 B | 1 B |
| Free CF | 931 M | 709 M | 283 M | 106 M |
| Capex | -148 M | -128 M | -195 M | -286 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -2.93% | -1.75% | — | — |
| Earnings Growth % | -5.34% | 73.64% | — | — |
| Profit Margin % | -27.97% | -25.78% | -96.07% | — |
| Operating Margin % | 13.72% | -4.93% | 7.72% | — |
| Gross Margin % | 65.44% | 60.92% | 64.83% | — |
| EBITDA Margin % | -16.58% | -13.5% | -85.43% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-06-25 | 1:1.028 |